We’re delighted to announce our place on the Buzzacott Organic Growth 25 list, which celebrates twenty-five of the fastest growing businesses in the UK.
Over the past two years, we’ve evolved to meet the changing needs of the clinical research industry at unprecedented rates.
Driven by our mission to deliver remarkable experiences at every stage of the patient journey, we’ve developed our digital products and services to ensure clinical excellence in decentralised and hybrid clinical trials.
The result has been a 101% growth in revenue in the last financial year with a suite of digital products launching in the coming months.
Our CEO, Tarquin Scadding-Hunt, says: “We are delighted with our inclusion in Buzzacott’s Organic Growth 25 as it honours the accomplishments of our remarkable team over the past 12 months. We’re investing hugely in research and development, creating innovative healthcare technology that tackles the ongoing challenges our clients face at each stage of a clinical trial.
“The COVID-19 pandemic has pushed a patient-centred approach to the top of big pharma’s agenda, and it has never been more important to listen to patient voices at every stage of the clinical journey.
“From issues with patient care and sentiment, to home healthcare provider visits and medical equipment, to burdensome payment workflows and reimbursements, mdgroup’s pioneering technology directly improves patient experience and trial outcomes.”
